Trademark: 88813300
Word
EBIOPARTICLE-POTENTIATED IMMUNOTHERAPY
Status Date
Thursday, March 9, 2023
Filing Date
Thursday, February 27, 2020
Abandoned Date
Monday, February 27, 2023
5 (Based on 44(d) Priority Application) (Based on Intent to Use) Protein arrays for medical diagnosis purposes; proteins arrays for therapeutic use for treating cancer, allergies, autoimmune disease, infection disease, and inflammatory disease; biopharmaceuticals for treatment of cancer, allergies, autoimmune disease, infection disease; pharmaceutical preparations for use in the treatment of allergy, cancer, infectious diseases and immune diseases; pharmacological preparations able to effect immunotherapy with specific attributes of potency and safety
1 (Based on 44(d) Priority Application) (Based on Intent to Use) Chemicals for use in the manufacture of pharmaceuticals; proteins for immunoassay for detection, for diagnostic purposes, for therapeutic purposes and for treatment of cancer, allergies, autoimmune disease, infection diseases; all of the foregoing expressly excluding biologically-derived particles that can be fluorescently-labeled for scientific research purposes
44 (Based on 44(d) Priority Application) (Based on Intent to Use) Medical services, namely, vaccinal pharmacologic treatment of autoimmune diseases such as psoriasis, Crohn's disease, rheumatoid arthritis, cancer, infectious diseases and allergies; health care services, namely, desensitization treatments for allergy; medical services, namely, immunotherapy in the fields of cancer, autoimmune, infectious disease and orphan diseases conditions in humans and veterinary applications; medical treatment of allergies, cancer, and auto-immune diseases destined to generate, in response to its administration in patients, the production of the patient's own antibodies
42 (Based on 44(d) Priority Application) (Based on Intent to Use) Development of pharmaceutical preparations and medicines; drug discovery services; software as a service (SAAS) services featuring artificial intelligence software for use in the pharmaceuticals and healthcare fields, namely, for diagnostic and therapeutic use, and for data mining in the field of providing pharmaceutical products in order to create as many therapeutic different therapeutic agents deemed in the pharmaceutical industry and nanoparticles; platform as a service (PAAS) services featuring artificial intelligence software platforms for use in the pharmaceuticals and healthcare fields, namely, for diagnostic and therapeutic use, and for data mining for use in the field of pharmacological and pharmaceutical products in order to create as many therapeutic different therapeutic agents deemed in the pharmaceutical industry and nanoparticles; platform as a service (PAAS) services featuring computer software platforms for use in the pharmaceuticals and healthcare fields, namely, for diagnostic and therapeutic use, and for data mining for use in the field of pharmacological and pharmaceutical applications that is an immunomodulatory vector on which biologic targets determine the pertinence and use of these pharmacological agents
EBIOPARTICLE POTENTIATED IMMUNOTHERAPY
"IMMUNOTHERAPY"
Mar 9, 2023
Abandonment Notice E-Mailed - Failure To Respond
Mar 9, 2023
Abandonment Notice Mailed - Failure To Respond
Mar 9, 2023
Abandonment - Failure To Respond Or Late Response
Jan 17, 2023
Assigned To Examiner
Aug 25, 2022
Notification Of Inquiry As To Suspension E-Mailed
Aug 25, 2022
Inquiry To Suspension E-Mailed
Aug 25, 2022
Suspension Inquiry Written
Aug 25, 2022
Suspension Checked - To Attorney For Action
Feb 24, 2022
Notification Of Letter Of Suspension E-Mailed
Feb 24, 2022
Letter Of Suspension E-Mailed
Feb 24, 2022
Suspension Letter Written
Feb 3, 2022
Teas/Email Correspondence Entered
Feb 3, 2022
Correspondence Received In Law Office
Jan 26, 2022
Teas Response To Suspension Inquiry Received
Sep 22, 2021
Notification Of Inquiry As To Suspension E-Mailed
Sep 22, 2021
Inquiry To Suspension E-Mailed
Sep 22, 2021
Suspension Inquiry Written
Mar 20, 2021
Notification Of Letter Of Suspension E-Mailed
Mar 20, 2021
Letter Of Suspension E-Mailed
Mar 20, 2021
Suspension Letter Written
Feb 22, 2021
Teas/Email Correspondence Entered
Feb 22, 2021
Correspondence Received In Law Office
Feb 22, 2021
Assigned To Lie
Nov 18, 2020
Teas Response To Office Action Received
May 18, 2020
Notification Of Non-Final Action E-Mailed
May 18, 2020
Non-Final Action E-Mailed
May 18, 2020
Non-Final Action Written
May 18, 2020
Assigned To Examiner
Mar 5, 2020
New Application Office Supplied Data Entered
Mar 5, 2020
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
